Akèy › Karsinòm selil skuamèz tèt ak kou › Minnesota › Rochester
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Rochester, MN
12 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Ap rekriteFaz 3
- Mayo Clinic in Rochester, Rochester
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ap rekriteFaz 2/3
- Site #0146, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #68, Rochester
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- Mayo Clinic (Rochester), Rochester
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- Mayo Clinic Rochester, Rochester
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Ap rekriteFaz 2/3
- Mayo Clinic in Rochester, Rochester
Oropharynx (OPX) Biomarker Trial
Ap rekriteEtid obsèvasyon
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Ap rekriteFaz 1
- Mayo Clinic Rochester, Rochester
Etid Karsinòm selil skuamèz tèt ak kou nan lòt vil
- Houston, TX47 etid
- Los Angeles, CA42 etid
- Boston, MA40 etid
- New York City, NY39 etid
- Nashville, TN39 etid
- St. Louis, MO28 etid
- Arlington, VA26 etid
- Philadelphia, PA26 etid
- Chicago, IL26 etid
- Atlanta, GA24 etid
- San Antonio, TX22 etid
- New Haven, CT22 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè Metastatik31 etid
- Kansè (tout kalite)30 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Myelom Miltip24 etid
- Ensifizyans kadyak22 etid
- Kansè pwostat22 etid
- Kansè pankreyas22 etid
- Kansè Endomèt20 etid
- Kansè poumon20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.